Arrowhead Pharmaceuticals Corp (ARWR) Reports In-Line Q3 EPS, Revenues Beat
Arrowhead Pharmaceuticals Corp (NASDAQ: ARWR) reported Q3 EPS of ($0.18), in-line with the analyst estimate of ($0.18). Revenue for the quarter came in at $727.38 thousand versus the consensus estimate of $690 thousand.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Corp (ARWR) click here.